{"id":250352,"date":"2026-09-16T17:25:32","date_gmt":"2026-09-16T11:55:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=250352"},"modified":"2026-09-16T17:25:33","modified_gmt":"2026-09-16T11:55:33","slug":"jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/","title":{"rendered":"Jagsonpal Pharmaceuticals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Jagsonpal Pharmaceuticals share price Rs 227.46 on 16 September 2026, up 0.72%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 13.00 crore. Q2 FY26 base a profit of Rs 13.00 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Jagsonpal Pharmaceuticals Q2 results date for FY27 is not confirmed, and Jagsonpal Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 74.00 crore in revenue and a profit of Rs 13.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.<\/p>\n<\/p><\/div>\n<p>The Jagsonpal Pharmaceuticals Q2 results FY27 announcement is the next scheduled earnings event for <a href=\"https:\/\/univest.in\/stocks\/jagsnpharm\/jagsonpal-pharmaceuticals-ltd-share-price-today\">Jagsonpal Pharmaceuticals Ltd.<\/a>, Jagsonpal Pharmaceuticals is a pharmaceutical company engaged in the manufacturing and marketing of formulations sold under its own brands across India.. The stock traded at Rs 227.46 on the NSE on 16 September 2026, up 0.72% from the previous close of Rs 225.83, about 14.0% below its 52-week high of Rs 264.50 and 46.7% above its 52-week low of Rs 155.00.<\/p>\n<p>What makes the Jagsonpal Pharmaceuticals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 74.00 crore of revenue and a profit of Rs 13.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 82.00 crore and a profit of Rs 13.00 crore. Everything below is built from those reported figures rather than from any forecast.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=jagsnpharm_q2_fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#When_Is_the_Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Date\" title=\"When Is the Jagsonpal Pharmaceuticals Q2 Results FY27 Date?\">When Is the Jagsonpal Pharmaceuticals Q2 Results FY27 Date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Jagsonpal_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\" title=\"Jagsonpal Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking\">Jagsonpal Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Jagsonpal_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\" title=\"Jagsonpal Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On\">Jagsonpal Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Q2_FY26_Base_The_Comparison_Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Must_Beat\" title=\"Q2 FY26 Base: The Comparison Jagsonpal Pharmaceuticals Q2 Results FY27 Must Beat\">Q2 FY26 Base: The Comparison Jagsonpal Pharmaceuticals Q2 Results FY27 Must Beat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Jagsonpal_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\" title=\"Jagsonpal Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters\">Jagsonpal Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Key_Factors_That_Could_Shape_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\" title=\"Key Factors That Could Shape Jagsonpal Pharmaceuticals Q2 Results FY27\">Key Factors That Could Shape Jagsonpal Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Valuation_Snapshot\" title=\"Valuation Snapshot\">Valuation Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Technical_and_Price_Context\" title=\"Technical and Price Context\">Technical and Price Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Balance_Sheet_and_Payout\" title=\"Balance Sheet and Payout\">Balance Sheet and Payout<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\" title=\"Jagsonpal Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print\">Jagsonpal Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_Investors_Should_Watch_When_Jagsonpal_Pharmaceuticals_Q2_Results_Are_Announced\" title=\"What Investors Should Watch When Jagsonpal Pharmaceuticals Q2 Results Are Announced\">What Investors Should Watch When Jagsonpal Pharmaceuticals Q2 Results Are Announced<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Conclusion_on_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\" title=\"Conclusion on Jagsonpal Pharmaceuticals Q2 Results FY27\">Conclusion on Jagsonpal Pharmaceuticals Q2 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#FAQs_on_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\" title=\"FAQs on Jagsonpal Pharmaceuticals Q2 Results FY27\">FAQs on Jagsonpal Pharmaceuticals Q2 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_the_Jagsonpal_Pharmaceuticals_Q2_results_date_for_FY27\" title=\"What is the Jagsonpal Pharmaceuticals Q2 results date for FY27?\">What is the Jagsonpal Pharmaceuticals Q2 results date for FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_quarter_do_the_Jagsonpal_Pharmaceuticals_Q2_results_2026_cover\" title=\"What quarter do the Jagsonpal Pharmaceuticals Q2 results 2026 cover?\">What quarter do the Jagsonpal Pharmaceuticals Q2 results 2026 cover?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_the_Jagsonpal_Pharmaceuticals_Q1_FY27_results\" title=\"What were the Jagsonpal Pharmaceuticals Q1 FY27 results?\">What were the Jagsonpal Pharmaceuticals Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_were_Jagsonpal_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\" title=\"What were Jagsonpal Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\">What were Jagsonpal Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_are_the_main_Jagsonpal_Pharmaceuticals_Q2_results_expectations_this_quarter\" title=\"What are the main Jagsonpal Pharmaceuticals Q2 results expectations this quarter?\">What are the main Jagsonpal Pharmaceuticals Q2 results expectations this quarter?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#What_is_Jagsonpal_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\" title=\"What is Jagsonpal Pharmaceuticals share price today ahead of the Q2 earnings?\">What is Jagsonpal Pharmaceuticals share price today ahead of the Q2 earnings?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations\/#Is_Jagsonpal_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\" title=\"Is Jagsonpal Pharmaceuticals a good stock to buy before the Q2 results?\">Is Jagsonpal Pharmaceuticals a good stock to buy before the Q2 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"When_Is_the_Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Date\"><\/span><strong>When Is the Jagsonpal Pharmaceuticals Q2 Results FY27 Date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Jagsonpal Pharmaceuticals Q2 results date for FY27 is not confirmed. As of 16 September 2026, Jagsonpal Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.<\/p>\n<p>What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Jagsonpal Pharmaceuticals Q2 results date becomes public through that filing rather than through any advance announcement.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/eris-lifesciences-q2-results-fy27-preview-date-expectations\">Eris Lifesciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>The Jagsonpal Pharmaceuticals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Jagsonpal Pharmaceuticals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Q2_Results_Expectations_What_the_Market_Is_Actually_Tracking\"><\/span><strong>Jagsonpal Pharmaceuticals Q2 Results Expectations: What the Market Is Actually Tracking<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No verified analyst estimate for the Jagsonpal Pharmaceuticals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Jagsonpal Pharmaceuticals. The Jagsonpal Pharmaceuticals Q2 results watchlist below is built from what the company has actually reported and disclosed.<\/p>\n<p>Jagsonpal Pharmaceuticals Q2 results for the September 2026 quarter follow a revenue pattern that has been broadly steady with one soft quarter in between. Quarterly sales came in at Rs76 crore in June 2025, Rs74 crore in September 2025, Rs73 crore in December 2025, then dipped to Rs64 crore in March 2026, before rebounding to Rs82 crore in June 2026, the highest reading in this five-quarter run. This shape gives useful context for Jagsonpal Pharmaceuticals Q2 results, since the business has shown it can recover quickly after a softer quarter rather than settling into a lower run rate. The jump in June 2026 revenue sets a firmer base heading into the September 2026 quarter, and observers tracking Jagsonpal Pharmaceuticals Q2 results will likely view the upcoming print against this recent bounce rather than against the March 2026 dip alone.<\/p>\n<p>Operating margin for Jagsonpal Pharmaceuticals has stayed within a relatively tight 17-22% band across the five quarters, moving from 19% in June 2025 to 22% in both September 2025 and December 2025, dipping to 17% in March 2026, and returning to 21% in June 2026. Net profit has tracked this pattern closely, ranging between Rs9 crore and Rs13 crore, with Rs11 crore in June 2025, Rs13 crore in September 2025, Rs11 crore in December 2025, Rs9 crore in March 2026, and back up to Rs13 crore in June 2026. For Jagsonpal Pharmaceuticals Q2 results, this consistency matters: there is no loss-making quarter or sharp one-off swing in this window, which makes the recent margin and profit band a reasonable reference point for how Jagsonpal Pharmaceuticals Q2 results might compare once reported, even though the outcome of Jagsonpal Pharmaceuticals Q2 results remains unknown until the company reports.<\/p>\n<p>Jagsonpal Pharmaceuticals trades at a trailing price to earnings ratio of about 32.7, a relatively rich multiple for a company of its size, alongside a return on equity of 17.3% and return on capital employed of 22.7%, both healthy for the pharmaceutical space. The dividend yield is modest at 1.72%. Unlike some peers in this results season, the main data-quality point here is not a loss or an anomaly, since the five quarters show stable margins with no one-off items flagged in the screener notes. That said, the rich valuation means Jagsonpal Pharmaceuticals Q2 results for the September 2026 quarter will likely be scrutinised closely for whether growth and margins can justify the current multiple, since Jagsonpal Pharmaceuticals Q2 results carry higher expectations than a lower-multiple stock would.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Jagsonpal Pharmaceuticals Ltd. Live Fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Q2_Results_Preview_The_Q1_FY27_Actuals_It_Builds_On\"><\/span><strong>Jagsonpal Pharmaceuticals Q2 Results Preview: The Q1 FY27 Actuals It Builds On<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 82.00 crore in Q1 FY27, up 7.89% from Rs 76.00 crore in Q1 FY26, and a profit of Rs 13.00 crore at the net level, up 18.18% from Rs 11.00 crore in Q1 FY26. These are reported actuals, not estimates.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/escorts-kubota-q2-results-fy27-preview-date-expectations\">Escorts Kubota Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter<\/a><\/p>\n<p>Sequentially, revenue was up 28.12% over the March 2026 quarter figure of Rs 64.00 crore, and net profit was up 44.44% from Rs 9.00 crore in Q4 FY26. Operating margin stood at 19.0% in Q1 FY27 against 22.0% in the September 2025 quarter, which is the comparison the Jagsonpal Pharmaceuticals Q2 results print will be read against.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY26_Base_The_Comparison_Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Must_Beat\"><\/span><strong>Q2 FY26 Base: The Comparison Jagsonpal Pharmaceuticals Q2 Results FY27 Must Beat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 74.00 crore and a profit of Rs 13.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Jagsonpal Pharmaceuticals Q2 results preview.<\/p>\n<p>Net profit in that base quarter was below the Rs 13.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 74.00 crore sits below the Rs 82.00 crore of the June 2026 quarter, which frames how much sequential movement the Jagsonpal Pharmaceuticals Q2 results print needs to show growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Quarterly_Results_Trend_Over_the_Last_Four_Quarters\"><\/span><strong>Jagsonpal Pharmaceuticals Quarterly Results Trend Over the Last Four Quarters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Q2 FY26 (Sep 2025)<\/td>\n<td>74.00<\/td>\n<td>13.00<\/td>\n<\/tr>\n<tr>\n<td>Q3 FY26 (Dec 2025)<\/td>\n<td>73.00<\/td>\n<td>11.00<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 (Mar 2026)<\/td>\n<td>64.00<\/td>\n<td>9.00<\/td>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>82.00<\/td>\n<td>13.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company&#8217;s exchange filings, and they are the only basis this Jagsonpal Pharmaceuticals Q2 results preview uses.<\/p>\n<p>Revenue across those four quarters ranged from Rs 64.00 crore to Rs 82.00 crore, and net profit from Rs 9.00 crore to Rs 13.00 crore. That spread is the honest context for the Jagsonpal Pharmaceuticals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Factors_That_Could_Shape_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Key Factors That Could Shape Jagsonpal Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Jagsonpal Pharmaceuticals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Jagsonpal Pharmaceuticals has already reported.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Snapshot\"><\/span><strong>Valuation Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Jagsonpal Pharmaceuticals trades at a price to earnings ratio of roughly 31.9, well above many small-cap pharmaceutical peers, with a book value of Rs41.2 per share translating into a price to book ratio of about 5.52, a fairly rich multiple to book. Return on equity of 17.3% is a healthy figure that helps explain part of the premium valuation, alongside a return on capital employed of 22.7%. The dividend yield is modest at 1.72%, indicating the company retains most of its earnings rather than distributing a large share of profit to shareholders each year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Technical_and_Price_Context\"><\/span><strong>Technical and Price Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The stock has traded between Rs155.0 and Rs264.5 over the past 52 weeks, with the current price of Rs227.46 sitting in the upper half of that range, closer to the highs than the lows. It trades just below its 50-day moving average of Rs232.11 but well above its 200-day moving average of Rs204.09, suggesting the medium-term trend has been upward even as short-term momentum has cooled somewhat in recent sessions. The relative strength index of 30.53 is on the lower side, closer to oversold territory than overbought, which can sometimes precede a period of price consolidation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Payout\"><\/span><strong>Balance Sheet and Payout<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity for Jagsonpal Pharmaceuticals is minimal at 0.03, meaning the company operates with almost no reliance on borrowings and funds its operations largely through internal accruals rather than external capital. This clean balance sheet supports steady, if modest, dividend payments, with the current dividend yield at 1.72%, reflecting a policy of retaining most profits for reinvestment into the business rather than large-scale cash distribution to shareholders. The near debt-free position also gives the company room to keep investing in its branded formulations business without added interest-cost pressure weighing on future quarters.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jagsonpal_Pharmaceuticals_Q2_Results_FY27_Share_Price_and_Valuation_Going_Into_the_Print\"><\/span><strong>Jagsonpal Pharmaceuticals Q2 Results FY27: Share Price and Valuation Going Into the Print<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jagsonpal Pharmaceuticals share price today is Rs 227.46 on the NSE, up Rs 1.63 or 0.72% from the previous close of Rs 225.83 on 16 September 2026, ahead of the Jagsonpal Pharmaceuticals Q2 results announcement.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value (16 September 2026)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NSE Symbol<\/td>\n<td>JAGSNPHARM<\/td>\n<\/tr>\n<tr>\n<td>Current Market Price<\/td>\n<td>Rs 227.46<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 264.50<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 155.00<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Rs 1499 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio<\/td>\n<td>31.92<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>5.52<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 7.13<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share<\/td>\n<td>Rs 41.20<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.03<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>17.30%<\/td>\n<\/tr>\n<tr>\n<td>50-Day Moving Average<\/td>\n<td>Rs 232.11<\/td>\n<\/tr>\n<tr>\n<td>200-Day Moving Average<\/td>\n<td>Rs 204.09<\/td>\n<\/tr>\n<tr>\n<td>RSI (14)<\/td>\n<td>30.53<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock trades below its 50-day average of Rs 232.11 but above its 200-day average of Rs 204.09, with a 14-day RSI of 30.53. None of this is a view on where the shares go once the Jagsonpal Pharmaceuticals Q2 results are announced, and no price target is offered here.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Jagsonpal Pharmaceuticals Ltd. live price and quarterly earnings updates.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_When_Jagsonpal_Pharmaceuticals_Q2_Results_Are_Announced\"><\/span><strong>What Investors Should Watch When Jagsonpal Pharmaceuticals Q2 Results Are Announced<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four lines carry most of the information in a company of this size, and reading them in order keeps the Jagsonpal Pharmaceuticals Q2 results print in proportion.<\/p>\n<ol>\n<li>Revenue against the Rs 74.00 crore reported in the September 2025 base quarter<\/li>\n<li>Net profit against a profit of Rs 13.00 crore in that same quarter<\/li>\n<li>Operating margin against 19.0% in Q1 FY27<\/li>\n<li>Any exceptional item, provision or one-off gain disclosed alongside the numbers<\/li>\n<\/ol>\n<p>A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Jagsonpal Pharmaceuticals Q2 results announcement should be read together with the notes to the results rather than the headline alone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_on_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>Conclusion on Jagsonpal Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Jagsonpal Pharmaceuticals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Jagsonpal Pharmaceuticals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.<\/p>\n<p>On that basis the Jagsonpal Pharmaceuticals Q2 results FY27 print faces a base of Rs 74.00 crore in revenue and a profit of Rs 13.00 crore, with the most recent quarter having delivered Rs 82.00 crore and a profit of Rs 13.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Jagsonpal Pharmaceuticals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Jagsonpal_Pharmaceuticals_Q2_Results_FY27\"><\/span><strong>FAQs on Jagsonpal Pharmaceuticals Q2 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Jagsonpal_Pharmaceuticals_Q2_results_date_for_FY27\"><\/span><strong>What is the Jagsonpal Pharmaceuticals Q2 results date for FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Jagsonpal Pharmaceuticals Q2 results date for FY27 is not confirmed. Jagsonpal Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_quarter_do_the_Jagsonpal_Pharmaceuticals_Q2_results_2026_cover\"><\/span><strong>What quarter do the Jagsonpal Pharmaceuticals Q2 results 2026 cover?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Jagsonpal Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Jagsonpal Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Jagsonpal Pharmaceuticals Q2 results filing also carries the notes to the accounts.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Jagsonpal_Pharmaceuticals_Q1_FY27_results\"><\/span><strong>What were the Jagsonpal Pharmaceuticals Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 82.00 crore in Q1 FY27 and a profit of Rs 13.00 crore at the net level. Revenue was up 7.89% versus Q1 FY26 and net profit was up 18.18% from Rs 11.00 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Jagsonpal_Pharmaceuticals_Q2_FY26_results_in_the_September_2025_quarter\"><\/span><strong>What were Jagsonpal Pharmaceuticals Q2 FY26 results in the September 2025 quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 74.00 crore and a profit of Rs 13.00 crore in Q2 FY26. Operating margin was 22.0%. Those figures form the base for the Jagsonpal Pharmaceuticals Q2 results FY27 comparison.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_Jagsonpal_Pharmaceuticals_Q2_results_expectations_this_quarter\"><\/span><strong>What are the main Jagsonpal Pharmaceuticals Q2 results expectations this quarter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No verified analyst estimate is publicly available. The Jagsonpal Pharmaceuticals Q2 results expectations centre on revenue against the Rs 74.00 crore base, net profit against a profit of Rs 13.00 crore, operating margin against 19.0% in Q1 FY27, and any exceptional item disclosed with the numbers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Jagsonpal_Pharmaceuticals_share_price_today_ahead_of_the_Q2_earnings\"><\/span><strong>What is Jagsonpal Pharmaceuticals share price today ahead of the Q2 earnings?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jagsonpal Pharmaceuticals share price is Rs 227.46 on the NSE as of 16 September 2026, up 0.72% from Rs 225.83. The stock is about 14.0% below its 52-week high of Rs 264.50 and 46.7% above its 52-week low of Rs 155.00, at a market capitalisation of Rs 1499 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Jagsonpal_Pharmaceuticals_a_good_stock_to_buy_before_the_Q2_results\"><\/span><strong>Is Jagsonpal Pharmaceuticals a good stock to buy before the Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, sell or hold recommendation on Jagsonpal Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 5.52 with a return on equity of 17.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Jagsonpal Pharmaceuticals Q2 results date for FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Jagsonpal Pharmaceuticals Q2 results date for FY27 is not confirmed. Jagsonpal Pharmaceuticals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.\"}},{\"@type\":\"Question\",\"name\":\"What quarter do the Jagsonpal Pharmaceuticals Q2 results 2026 cover?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Jagsonpal Pharmaceuticals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Jagsonpal Pharmaceuticals Ltd. reports revenue, operating profit and net profit for that period, and the Jagsonpal Pharmaceuticals Q2 results filing also carries the notes to the accounts.\"}},{\"@type\":\"Question\",\"name\":\"What were the Jagsonpal Pharmaceuticals Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 82.00 crore in Q1 FY27 and a profit of Rs 13.00 crore at the net level. Revenue was up 7.89% versus Q1 FY26 and net profit was up 18.18% from Rs 11.00 crore in Q1 FY26.\"}},{\"@type\":\"Question\",\"name\":\"What were Jagsonpal Pharmaceuticals Q2 FY26 results in the September 2025 quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Jagsonpal Pharmaceuticals Ltd. reported revenue of Rs 74.00 crore and a profit of Rs 13.00 crore in Q2 FY26. Operating margin was 22.0%. Those figures form the base for the Jagsonpal Pharmaceuticals Q2 results FY27 comparison.\"}},{\"@type\":\"Question\",\"name\":\"What are the main Jagsonpal Pharmaceuticals Q2 results expectations this quarter?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No verified analyst estimate is publicly available. The Jagsonpal Pharmaceuticals Q2 results expectations centre on revenue against the Rs 74.00 crore base, net profit against a profit of Rs 13.00 crore, operating margin against 19.0% in Q1 FY27, and any exceptional item disclosed with the numbers.\"}},{\"@type\":\"Question\",\"name\":\"What is Jagsonpal Pharmaceuticals share price today ahead of the Q2 earnings?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Jagsonpal Pharmaceuticals share price is Rs 227.46 on the NSE as of 16 September 2026, up 0.72% from Rs 225.83. The stock is about 14.0% below its 52-week high of Rs 264.50 and 46.7% above its 52-week low of Rs 155.00, at a market capitalisation of Rs 1499 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is Jagsonpal Pharmaceuticals a good stock to buy before the Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, sell or hold recommendation on Jagsonpal Pharmaceuticals Ltd. The stock trades at a price-to-book ratio of 5.52 with a return on equity of 17.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jagsonpal Pharmaceuticals Q2 results FY27 date is not yet confirmed by the exchanges. Here is the September 2026 quarter watchlist for Jagsonpal Pharmaceuticals Ltd., built on actual Q1 FY27 and Q2 FY26 numbers with no invented estimates.<\/p>\n","protected":false},"author":29,"featured_media":250350,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5331],"tags":[],"class_list":["post-250352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-https-univest-in-blogs-category-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["250350"],"rank_math_title":["Jagsonpal Pharma Q2 FY27 Preview: Margin, Valuation"],"rank_math_description":["Jagsonpal Pharmaceuticals Q2 results FY27 preview: results date status, key expectations, Q1 FY27 and Q2 FY26 actuals plus valuation before the September 2026 print."],"rank_math_focus_keyword":["Jagsonpal Pharmaceuticals Q2 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/jagsonpal-pharmaceuticals-q2-results-fy27-preview-date-expectations.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/250352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=250352"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/250352\/revisions"}],"predecessor-version":[{"id":250353,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/250352\/revisions\/250353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/250350"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=250352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=250352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=250352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}